FDA Panel Views On PFS Endpoint For Avastin Could Impact Fate Of Other First-Line Cancer Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Panel’s rejection of Genentech sBLA for first-line breast cancer despite meeting endpoint of progression-free survival leaves Wall Street wondering if same fate will befall ImClone/Bristol’s Erbitux in colon cancer.
You may also be interested in...
The Endgame on Oncology Endpoints
The annual ASCO meeting, held in Chicago this year, provided a forum for investigators to discuss the merits of continued use of progression-free survival as an endpoint in oncology clinical trials. Phase III data from Roche/Genentech's Avastin in metastatic breast cancer sparked debate.
Pharmacyclics’ Xcytrin Gets FDA “Not Approvable” For NSCLC Patients With Brain Metastases
CEO Richard Miller calls for FDA to release the “biotech bottleneck” caused by its approvals process.
Pharmacyclics’ Xcytrin Gets FDA “Not Approvable” For NSCLC Patients With Brain Metastases
CEO Richard Miller calls for FDA to release the “biotech bottleneck” caused by its approvals process.